This study aimed to investigate the pattern of cellular proliferation and to calculate the growth fraction of small intestinal crypts in 24 patients -eight with untreated coeliac disease (CD), six with treated CD, and 10 controls with normal villous architecture. Duodenal biopsy specimens were stained with MI-Bi antibody using an immunoperoxidase method. Positive stained crypt cells were counted and their position within each intact crypt column was noted. These were used to construct proliferation index distribution curves for each cell position from which the crypt growth fraction for each group of patients was calculated. The crypt growth fraction was found to be higher in the untreated CD group (0.57) than in the treated patients (0.39) and the controls (0.44). The mean (SEM) proliferative index for each crypt was significantly higher in the untreated group (42.3 (10.8)%; p<0.05) than in the treated CD (21.7 (8.5)%) and control (19.7 (7.5)°/0) groups and correlated closely with the surface:volume index and enterocyte cell height measurements in all three groups. An increased growth fraction may contribute to other changes in crypt cell kinetics to produce the histological changes seen in untreated CD. (Gut 1995; 36: 22-27) 
mediators from cells involved in the cell mediated response to gluten. These may affect crypt cell proliferation and epithelial cell toxicity by different pathways.
The monoclonal antibody MI-B 1 was developed in the Institute of Pathology, Kiel University, Germany.3 It is a murine IgG antibody which recognises a nuclear antigen consisting of 395 kDa and 345 kDa parts. Staining with MI-B 1 increases through the cell cycle from GI to G2 but sharply reduces after mitosis and is totally absent in Go. It has been shown by western blotting that MI-B1 recognises the same antigen as Ki-67 and therefore stains cells in all parts of the cell cycle.4
Previously, Ki-67 work was only possible on frozen sections as the epitope which the antibody recognises is concealed by tissue fixation. MI-B 1 recognises the Ki-67 antigen equally well in microwaved formalin fixed and wax embedded sections as in frozen sections.5 6 The advantage of using MI-B1 is that it allows the study of archive material with better preservation of morphology within the tissues studied allowing a more accurate assessment of parameters such as the enterocyte cell height and surface:volume index (S:V) which are indicators of toxicity in coeliac disease mucosa.7
Within the small bowel, crypt cell division is thought to originate from pluirpotent stem cells which are located in the basal portion8 passing through the middle or proliferative zone of the crypt and emerging near the mouth of the crypt as functional non-proliferating cells. With the onset of the inflammatory process, it has been suggested that the proliferative compartment may expand to occupy a larger part of the crypt, however, previous attempts at estimating crypt growth fraction by identifying cells in mitosis showed a reduction of the growth fraction in untreated CD crypts.
Our aim was to study the change in the crypt growth fraction in coeliac disease mucosa, to see how this varies on treatment with a gluten free diet, and the relation between total crypt cell labelling index and other known markers of toxicity in this disease. Taken together with other data on crypt cell kinetics, the results will help us to understand the mechanisms by which the characteristic mucosal lesion develops. The results may be of help as a baseline study for investigating the role of individual cytokines and growth factors in causing this lesion. An estimate of growth fraction using MI-B 1 
STATISTICS
Statistical analysis of differences between groups was done using the Student's unpaired t test. Analysis of the correlation between variables was performed by Spearman signed rank correlation. Differences were considered significant if a p value of less than 5% was obtained.
Results
The results show a significant increase in the duodenal crypt length by counting the number of cells per intact crypt length in untreated coeliac disease when compared with patients with treated coeliac disease and normal controls (p<0 05 each). There was a significant reduction in the surface to volume index (S:V) and a significant reductio n the enterocyte cell height in the untreated CD group (p<0 05 each) compared with the other two groups.
There was no significant difference in any of these parameters between the treated CD and control groups except for the S:V index which was just significantly less in the treated CD group (p=0.049) (see Table I ). Staining with the monoclonal antibody MI-B 1 produced a clearly visible brown coloration of crypt cells in cycle which was subjectively greater in the untreated CD group than the other two groups. This staining pattern obtained was evenly distributed throughout each section. Slides were coded and assessed blindly by a second observer and Table II ) but significantly raised in the upper, middle, and lower thirds of the crypts when these were divided equally after counting of crypt cells sequentially, thus suggesting the presence of an expanded number of cells in division (Fig 5) . This was considered in detail when the size of the proliferative compartment was calculated for each patient group by constructing proliferation index distribution curves (see Fig 6) . From these curves the half maximum point was found to be doubled in the untreated CD group (cell position 47) compared with the treated (cell position 24) and control groups (cell position 22). This reflected an increase in growth fraction in the untreated CD group (47/82,0.57) compared with treated CD (24/62,0.39) and control (22/50,0.44) groups. Importantly there was little difference in any of the proliferation data obtained for the treated CD and control groups.
The increase in individual crypt labelling index correlated very closely with the other known indices of toxicity in CD, namely a reduction in enterocyte cell height and surface area to volume index (Fig 7) .
Discussion
Our findings show that the proliferating crypt cell compartment in the untreated CD group covered a greater portion of the expanded crypt. We have been able to quantify this proliferative response using MI-B1. Changes in the crypt proliferation index detected by MI-B 1 correlated with the known indices of toxicity in CD, enterocyte cell height and surface area to volume index with crypt proliferation index.
An important observation is that we found an increase in the growth fraction of small intestinal crypts in the untreated coeliac disease group. Previous work involved only the counting of crypt cell mitotic figures and suggested that the growth fraction was decreased in untreated CD due to the massive increase in the total crypt cell population over Importantly there was no significant difference in the pattern ofstaining between the lat two groups. *Denotes p<0 05 compared with control.
the method we used recognised cells in the stages of the cell cycle. The increase growth fraction will contribute, together wi previously shown increase in the crypt migration rate and a halving of the cell c duration, to cause the massive elongatior crypts and apparent villous flattening whic seen in untreated CD. In normal tissue proliferative compartment is present in middle to lower third, as is also the case treated CD patients, and it is that the alte immunological microenvironment wi occurs in untreated CD results in the stimi tion of normally quiescent cells higher up crypt. The next task will be to determine v; cellular events initiate these changes in kinetics.
The control of gastrointestinal cell r liferation is thought to be regulated by ti main mechanisms, a local feedback from functional to the reproductive compone luminal nutrition, and a change in local systemic peptides and growth factors. ' the last mechanism is thought to be of greatest importance. Evidence obtained from studies involving gluten challenge indicate that crypt hyperplasia occurs at an earlier stage to any observed reduction in enterocyte cell height and that the theory implicating enterocyte shedding resulting in stimulation of crypt hyperplasia may not be valid in this disease. 20 It has also been shown in an in vitro system that crypt cell hyperplasia and villous flattening can occur without a change in enterocyte cell height.21 However, there is little work which conclusively shows that any specific T cell released factor can cause an increase in crypt cell proliferation in vivo. Work with a fetal organ culture system has shown that stimu- 
